Differentially expressed genes PCCA, ECHS1, and HADH are potential prognostic biomarkers for gastric cancer

Sci Prog. 2021 Apr-Jun;104(2):368504211011344. doi: 10.1177/00368504211011344.

Abstract

Gastric cancer (GC) is one of the most common malignant tumors in the world. As far as we know, no biomarker has been widely accepted for early diagnosis and prognosis prediction of GC. The purpose of this study is to find potential biomarkers to predict the prognosis of GC. The differentially expressed gene (DEG) was analyzed from GSE93774. Enrichr was used to analyze the gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, the enrichment of transcription factors (TF), miRNA, and kinase. GO analysis showed DEGs was enriched in the process of amino acid metabolism. Pathway results showed DEGs was mainly enriched in cell cycle. Propionyl CoA carboxylase alpha (PCCA), Enoyl coenzyme A hydratase short chain 1 (ECHS1), and 3-hydroxyacyl-CoA dehydrogenase (HADH) have prognostic value in patients with GC. ECHS1 and HADH genes were significantly associated with disease-free survival. There was a significant correlation between PCCA and overall survival rate. The results of this study suggest that PCCA, ECHS1, and HADH may be new biomarkers for predicting the prognosis of GC.

Keywords: Gastric cancer; biomarker; differentially expressed genes; microarray; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Hydroxyacyl-CoA Dehydrogenase* / genetics
  • Biomarkers, Tumor / genetics
  • Enoyl-CoA Hydratase* / genetics
  • Gene Expression Profiling / methods
  • Humans
  • Methylmalonyl-CoA Decarboxylase*
  • Prognosis
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / genetics
  • Stomach Neoplasms* / metabolism

Substances

  • Biomarkers, Tumor
  • 3-Hydroxyacyl-CoA Dehydrogenase
  • ECHS1 protein, human
  • Enoyl-CoA Hydratase
  • Methylmalonyl-CoA Decarboxylase